Adam Williams, MD
Allergy & Immunology · Bend, ORNPI 1265433445
Payments from drug & device makers
Across 515 payments — averaging $269.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$56K
- Sanofi$37K
- Genentech USA, Inc.$34K
- Amgen$6K
- Cumberland Pharmaceuticals, Inc.$1K
- GSK$852
- plus $4K from 22 others
What the payments were for
- Consulting fees$2,9012%
- Speaking & faculty fees$112,19581%
- Travel & lodging$11,5788%
- Food & beverage$11,3718%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 126 | $56,282 |
| Sanofi | 66 | $37,182 |
| Genentech USA, Inc. | 103 | $34,037 |
| Amgen | 27 | $5,709 |
| Cumberland Pharmaceuticals, Inc. | 1 | $1,000 |
| GSK | 44 | $852 |
| Novartis | 19 | $626 |
| Regeneron Healthcare Solutions, Inc. | 31 | $625 |
| CSL Behring | 35 | $551 |
| Blueprint Medicines Corporation | 5 | $375 |
| AbbVie | 9 | $233 |
| Optinose US, Inc. | 10 | $180 |
| Sanofi-aventis U.S. LLC | 2 | $175 |
| Lilly USA, LLC | 3 | $158 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $120 |
| Regeneron | 1 | $110 |
| Biocryst US Sales Co., LLC | 1 | $110 |
| Bio Products Laboratory USA, Inc. | 5 | $90 |
| Grifols USA, LLC | 4 | $89 |
| Boehringer Ingelheim | 5 | $84 |
| Merck | 1 | $75 |
| Octapharma USA, Inc. | 2 | $71 |
| Ionis Pharmaceuticals, Inc. | 2 | $60 |
| Pharming Healthcare, Inc. | 1 | $50 |
| Teva Pharmaceuticals USA, Inc. | 2 | $40 |
| Biocryst Pharmaceuticals, Inc. | 1 | $22 |
| Circassia Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$139,045 in reported general payments places this provider in the 75th percentile of 33 allergy & immunology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 15 | $782,901 |
| Dupixent SyringeDupilumab | 45 | $205,456 |
| Dupixent PenDupilumab | 36 | $129,549 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 12 | $103,058 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 17 | $57,392 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 74 | $55,858 |
| Breo ElliptaFluticasone/Vilanterol | 46 | $22,371 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 42 | $7,862 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 24 | $7,600 |
| DuleraMometasone/Formoterol | 14 | $6,863 |
| Fluticasone Propionate HfaFluticasone Propionate | 17 | $5,574 |
| Ipratropium Bromide | 172 | $5,504 |
| QnaslBeclomethasone Dipropionate | 15 | $5,419 |
| Advair DiskusFluticasone Propion/Salmeterol | 20 | $5,295 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 31 | $4,653 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $120 | $782,90115 claims |
| Bio Products Laboratory USA, Inc.Gammaplex | $90 | $103,05812 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $852 | $78,230120 claims |
| CSL BehringHizentra | $551 | $57,39217 claims |
| Teva Pharmaceuticals USA, Inc.Qnasl, Qvar Redihaler | $40 | $9,53828 claims |
| MerckDulera | $75 | $6,86314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 33 allergy & immunology providers in Oregon.
Other allergy & immunology in Bend
- Anthony MontanaroPortland$3.5M
- Stephen FritzHappy Valley$274K
- Shyam JoshiPortland$251K
- Gregory OwensPortland$235K
- Kraig JacobsonEugene$199K
- Ryan IsraelsenMedford$167K
- Sarah KehlEugene$163K
- Roland SolenskyCorvallis$52K
- Karen AnsteyPortland$20K
- Michael OsbornePortland$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.